VerastemVSTM
Fair Value
US$20
Share price06 Jan
US$6.0369.9% undervalued intrinsic discount
1Y16.86%
7D9.04%
RAS MAPK Therapies And Expanding Trials Will Transform This Rare Cancer Specialist
AN
Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls
Published
06 Jan 26
Views
30
Not Invested